Judge Fallon presiding over Xarelto MDL 2592 also denied a motion for new bellwether trials for the plaintiffs who had lost to the defendants in the first two bellwethers trials. The judge stood by his decisions stating that they were made on the right grounds. The plaintiffs had filed the motions highlighting the fact that certain data was deemed inadmissible by the court to be a part of the trials as it included international information. The plaintiffs also emphasized that the jury was informed to consider the drug manufacturers were required to disclose only the FDA approved tests to the patients that clearly excluded the prothrombin time test, which is a part of international labels, but not FDA approved.
Recent News
Roundup Lawsuits in New Jersey Seek Centralization
03/04/2024 - 17:33
A request has been filed by a group of plaintiffs urging the consolidation of all Roundup lawsuits related to non-Hodgkin’s lymphom…
Learn More
Baltimore Settles in Walmart Opioid Cases
03/03/2024 - 20:48
The mayor of Baltimore, representing the City, has endorsed a statewide settlement with Walmart to address the corporation's allege…
Learn More
Opioid Crisis: Fentanyl and Meth Drive 'Fourth Wave…
02/27/2024 - 21:02
The United States is currently grappling with what some experts identify as the "fourth wave" of the opioid epidemic, presenting in…
Learn More
Oregon Re-evaluates Decriminalization Amid Opioid Crisis
02/20/2024 - 16:46
In 2020, Oregonians approved a groundbreaking ballot measure, known as Measure 110, establishing the most progressive drug law in t…
Learn More